|
|
 Previous Article | Table of Contents | Next Article 
Shed tumor gangliosides and progression of human neuroblastoma
L Valentino, T Moss, E Olson, HJ Wang, R Elashoff and S Ladisch
Department of Pediatrics, UCLA School of Medicine 90024-1752.
Shedding of membrane gangliosides is characteristic of human and
experimental tumors. Because some shed tumor gangliosides have potent
tumor-enhancing properties, significant ganglioside shedding could
influence tumor progression. We examined this possibility in a human tumor,
neuroblastoma. Ganglioside shedding, measured as circulating tumor-derived
GD2 ganglioside, and the outcome of 74 patients with advanced stage (III
and IV) disease were studied. Progression-free survival (PFS) was inversely
related to circulating GD2 levels at the time of diagnosis (P = .018). By
Kaplan-Meier analysis, the quartile of patients having the highest
circulating GD2 levels (greater than or equal to 568 pmol/mL) had a
strikingly different outcome from the quartile of patients with the lowest
(less than or equal to 103 pmol/mL) GD2 levels (P = .013): median PFS was
shorter (9 v 28 months), and the long-term survival rate lower (2-year PFS
of 24% v 70%). We conclude that more rapid disease progression and lower
survival rate are associated with high circulating GD2 levels at diagnosis
and speculate that shed neuroblastoma tumor gangliosides play a role in
accelerating tumor progression.
Volume 75,
Issue 7,
pp. 1564-1567,
04/01/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. de Leon, A. Fernandez, M. Clavell, M. Labrada, Y. Bebelagua, C. Mesa, and L. E. Fernandez
Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function
Int. Immunol.,
April 1, 2008;
20(4):
591 - 600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Shen, K. Stone, A. Jales, D. Leitenberg, and S. Ladisch
Inhibition of TLR Activation and Up-Regulation of IL-1R-Associated Kinase-M Expression by Exogenous Gangliosides
J. Immunol.,
April 1, 2008;
180(7):
4425 - 4432.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Das, G. Sa, C. Hilston, D. Kudo, P. Rayman, K. Biswas, L. Molto, R. Bukowski, B. Rini, J. H. Finke, et al.
GM1 and Tumor Necrosis Factor-{alpha}, Overexpressed in Renal Cell Carcinoma, Synergize to Induce T-Cell Apoptosis
Cancer Res.,
March 15, 2008;
68(6):
2014 - 2023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Liu, J. McCarthy, and S. Ladisch
Membrane Ganglioside Enrichment Lowers the Threshold for Vascular Endothelial Cell Angiogenic Signaling
Cancer Res.,
November 1, 2006;
66(21):
10408 - 10414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Chahlavi, P. Rayman, A. L. Richmond, K. Biswas, R. Zhang, M. Vogelbaum, C. Tannenbaum, G. Barnett, and J. H. Finke
Glioblastomas Induce T-Lymphocyte Death by Two Distinct Pathways Involving Gangliosides and CD70
Cancer Res.,
June 15, 2005;
65(12):
5428 - 5438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Rayman, A. K. Wesa, A. L. Richmond, T. Das, K. Biswas, G. Raval, W. J. Storkus, C. Tannenbaum, A. Novick, R. Bukowski, et al.
Effect of Renal Cell Carcinomas on the Development of Type 1 T-Cell Responses
Clin. Cancer Res.,
September 15, 2004;
10(18):
6360S - 6366S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Castriconi, A. Dondero, R. Augugliaro, C. Cantoni, B. Carnemolla, A. R. Sementa, F. Negri, R. Conte, M. V. Corrias, L. Moretta, et al.
Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis
PNAS,
August 24, 2004;
101(34):
12640 - 12645.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. V. Thornton, D. Kudo, P. Rayman, C. Horton, L. Molto, M. K. Cathcart, C. Ng, E. Paszkiewicz-Kozik, R. Bukowski, I. Derweesh, et al.
Degradation of NF-{kappa}B in T Cells by Gangliosides Expressed on Renal Cell Carcinomas
J. Immunol.,
March 15, 2004;
172(6):
3480 - 3490.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Zhang and F. L. Kiechle
Glycosphingolipids in Health and Disease
Ann. Clin. Lab. Sci.,
January 1, 2004;
34(1):
3 - 13.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hettmer, C. Malott, W. Woods, S. Ladisch, and K. Kaucic
Biological Stratification of Human Neuroblastoma by Complex "B" Pathway Ganglioside Expression
Cancer Res.,
November 1, 2003;
63(21):
7270 - 7276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Weiss, S. Hettmer, P. Smith, and S. Ladisch
Inhibition of Melanoma Tumor Growth by a Novel Inhibitor of Glucosylceramide Synthase
Cancer Res.,
July 1, 2003;
63(13):
3654 - 3658.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Kudo, P. Rayman, C. Horton, M. K. Cathcart, R. M. Bukowski, M. Thornton, C. Tannenbaum, and J. H. Finke
Gangliosides Expressed by the Renal Cell Carcinoma Cell Line SK-RC-45 Are Involved in Tumor-induced Apoptosis of T Cells
Cancer Res.,
April 1, 2003;
63(7):
1676 - 1683.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. V. Shurin, M. R. Shurin, S. Bykovskaia, J. Shogan, M. T. Lotze, and E. M. Barksdale Jr.
Neuroblastoma-derived Gangliosides Inhibit Dendritic Cell Generation and Function
Cancer Res.,
January 1, 2001;
61(1):
363 - 369.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. G. Manfredi, S. Lim, K. P. Claffey, and T. N. Seyfried
Gangliosides Influence Angiogenesis in an Experimental Mouse Brain Tumor
Cancer Res.,
October 1, 1999;
59(20):
5392 - 5397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. McKallip, R. Li, and S. Ladisch
Tumor Gangliosides Inhibit the Tumor-Specific Immune Response
J. Immunol.,
October 1, 1999;
163(7):
3718 - 3726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F.-Q. Wen, A. A. Jabbar, D. A. Patel, T. Kazarian, and L. A. Valentino
Atherosclerotic Aortic Gangliosides Enhance Integrin-Mediated Platelet Adhesion to Collagen
Arterioscler. Thromb. Vasc. Biol.,
March 1, 1999;
19(3):
519 - 524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
